Altimmune reported financial results for Q4 and full year 2021

Share price and report

US-based Altimmune (NASDAQ: ALT) today released a report with results for Q4th and full year 2021.

The company's shares closed at $6.43 in yesterday's trading. Also, in the past five days, the maximum value per share was US$7.62 and the minimum value was US$6.43.

The company's 52-week high is US$19.46 and the 52-week low is US$6.35.

It is worth noting that the company has a market capitalisation of USD 255.52 million.

Report from Altimmune

The company stated in its report that it had cash, cash equivalents, short-term investments and restricted cash totaling $190.3 million as of December 31, 2021.

Revenue for the three months was US$3.3 million.

Research and development expenses for the three months ended December 31, 2021 were $20.2 million.

Net loss for the three months ended December 31, 2021 was US$ 23.9 million.

Altimmune is a Biotech. and Drugs company which was founded in 1997. Thus, Vipin K. Garg is President and CEO at the company, Scot Roberts is Chief Scientific Officer at Altimmune, Richard Eisenstadt is CFO of the company, M. Scott Harris is Chief Medical Officer, Bertrand Georges is Chief Technology Officer and Jose Ochoa is CBO at Altimmune.